LexaGene to unveil LX2 beta prototype for veterinary marketOctober 10, 2018LexaGene Holdings Inc., a biotechnology company that develops instrumentation for pathogen detection, plans to unveil a model of its low-cost LX2 beta prototype at the American Association of Veterinary Laboratory Diagnosticians conference, Oct. 19-20 in Kansas City, Mo. The company's polymerase chain reaction-based technology is designed to be placed in-clinic, where it can screen samples for multiple targets simultaneously and return results in one hour. The LX2 system is low cost, leaves a small footprint and takes less than a minute to initiate automated sample processing. LX2 beta instrument features include: Ability to accept two distinct reagent panels for syndromic-based testing, where each panel is capable of detecting 28 targets (up to 56 targets total) at once Capability to process two samples at once within a footprint that measures 16 x 20 x 22 in. A one-time disposable cartridge per test "Incorporating this technology into a veterinary practice will provide better patient outcomes since the technology also looks for antimicrobial resistance, which will allow clinicians to make more informed decisions on prescribing the appropriate antibiotic," said Jack Regan, PhD, LexaGene CEO. "Furthermore, by bringing the testing in-house, practices will tap into a valuable revenue stream that …
SPONSORED CONTENTAre Your Patients Fully Protected?Fleas, ticks, heartworms, and intestinal parasites—dogs face multiple threats. See how a multi-parasite approach can offer your patients a broad range of protection. + Learn More
LexaGene, Ethos Veterinary Health partner for pathogen detection testingApril 6, 2018LexaGene has partnered with Ethos Veterinary Health, which has hospitals across the U.S., to test canine urine samples on LexaGene's prototype LX6 diagnostic tool for more effective, rapid and on-site pathogen detection. The samples have been previously characterized using conventional technologies such as MALDI-TOF mass spectrometry at LexaGene's reference laboratory, the company said. The organization is currently developing the LX6 tool as an open access, fully automated platform that allows end users to load real-time PCR assays. It will process six samples at a time and return results in around an hour, according to the company. "Veterinarians at Ethos will send LexaGene clinical annotated samples for processing, which will allow our team to continue to fine-tune and perfect our pathogen detection prototype's testing capabilities," said Jack Regan, Ph.D., LexaGene CEO. "This process is vital as we improve sensitivity to different isolates. We expect this to be a long-lasting collaboration as we work together to bring the best product possible to the veterinary market." "We've recently performed a market assessment for LexaGene's technology by interviewing many emergency and critical care veterinarians, and—coupled with an internal financial assessment of the cost of conventional testing versus …
